194 related articles for article (PubMed ID: 33194568)
21. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
22. Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis.
Roy AM; Jiang C; Perimbeti S; Deng L; Shapiro CL; Gandhi S
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686540
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
Berdunov V; Millen S; Paramore A; Griffin J; Reynia S; Fryer N; Brown R; Longworth L
Clinicoecon Outcomes Res; 2022; 14():619-633. PubMed ID: 36157054
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis.
Stabellini N; Cao L; Towe CW; Luo X; Amin AL; Montero AJ
Front Oncol; 2023; 13():1115208. PubMed ID: 37168373
[TBL] [Abstract][Full Text] [Related]
26. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
[TBL] [Abstract][Full Text] [Related]
27. Oncotype DX
Pease AM; Riba LA; Gruner RA; Tung NM; James TA
Ann Surg Oncol; 2019 Feb; 26(2):366-371. PubMed ID: 30542840
[TBL] [Abstract][Full Text] [Related]
28. 21-Gene Recurrence Score Assay Could Not Predict Benefit of Post-mastectomy Radiotherapy in T1-2 N1mic ER-Positive HER2-Negative Breast Cancer.
Zhang WW; Tong Q; Sun JY; Hua X; Long ZQ; Deng JP; Dong Y; Li FY; He ZY; Wu SG; Lin HX
Front Oncol; 2019; 9():270. PubMed ID: 31041190
[No Abstract] [Full Text] [Related]
29. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
[TBL] [Abstract][Full Text] [Related]
30. 21-Gene Recurrence Score Testing in HER2-positive Patients.
Altman AM; Marmor S; Tuttle TM; Hui JYC
Clin Breast Cancer; 2019 Apr; 19(2):126-130. PubMed ID: 30595493
[TBL] [Abstract][Full Text] [Related]
31. Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score.
Al-Zawi ASA; Yin SL; Aladili Z
Contemp Oncol (Pozn); 2022; 26(2):139-143. PubMed ID: 35903213
[TBL] [Abstract][Full Text] [Related]
32. Recurrence Score
Dannehl D; Engler T; Volmer LL; Staebler A; Fischer AK; Weiss M; Hahn M; Walter CB; Grischke EM; Fend F; Taran FA; Brucker SY; Hartkopf AD
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358784
[TBL] [Abstract][Full Text] [Related]
33. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
[TBL] [Abstract][Full Text] [Related]
34. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
35. The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.
Luo Y; Gao Y; Niu Z; Zhang J; Liu Z; Zhang Y; Shen S; Jiang Y; Xiao M; Zhu Q
Quant Imaging Med Surg; 2024 May; 14(5):3519-3533. PubMed ID: 38720854
[TBL] [Abstract][Full Text] [Related]
36. Utility of Oncotype DX in Male Breast Cancer Patients and Impact on Chemotherapy Administration: A Comparative Study with Female Patients.
Williams AD; McGreevy CM; Tchou JC; De La Cruz LM
Ann Surg Oncol; 2020 Oct; 27(10):3605-3611. PubMed ID: 32472417
[TBL] [Abstract][Full Text] [Related]
37. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
38. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
[TBL] [Abstract][Full Text] [Related]
40. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]